Actuate Therapeutics Inc (ACTU) vs Neuphoria Therapeutics Inc. (NEUP)
A side-by-side comparison of Actuate Therapeutics Inc and Neuphoria Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACTU
Actuate Therapeutics Inc
$0.83HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
NEUP
Neuphoria Therapeutics Inc.
$3.49HealthcareDelayed quote: Oct 6, 2026, 11:43 AM EDT
Total return — ACTU vs NEUP
growth of $100 · dividends reinvested · last 2yACTU -89.8% (-68.1%/yr)NEUP -52.5% (-31.1%/yr)NEUP compounded faster over this window
ACTU NEUP
ACTU vs NEUP: by the numbers
- •ACTU is the larger company ($20M vs $19M market cap).
- •Both run net losses; ACTU's is the smaller (0.00% vs -1578.40% net margin).
Metrics side by side
Valuation
| Metric | ACTU | NEUP |
|---|---|---|
| P/S ratio | N/A | 16.06 |
| P/B ratio | 20.08 | 0.77 |
Profitability
| Metric | ACTU | NEUP |
|---|---|---|
| Gross margin | 0.00% | 43.54% |
| Operating margin | 0.00% | -835.53% |
| Net margin | 0.00% | -1578.40% |
| ROE | -2067.81% | -75.34% |
| ROIC | -1489.99% | -49.83% |
Growth (annualized)
| Metric | ACTU | NEUP |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 11.12% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.